Berry Smith acted for AIM listed Yourgene Health Plc, the international molecular diagnostics group on its acquisition of Delta Diagnostics (UK) Limited, which trades as Elucigene, for a consideration of £9.2 million.
Elucigene is a Manchester based, molecular diagnostics manufacturer and developer, whose products focus on reproductive health and oncology, including products for cystic fibrosis and pre-natal aneuploidy screening.
Yourgene Health Plc is an international molecular diagnostics group which develops and commercialises genetic products and services, working in partnership with leaders in DNA technology to advance diagnostic science.
Andrew Bound, Corporate Partner, and Paul Evans, Senior Associate, lead the team at Berry Smith which acted on the transaction.
Andrew commented “We are delighted to work with the team at Yourgene to structure and complete the acquisition within a very tight timeline. The acquisition of Elucigene will provide Yourgene with further opportunities to develop and launch additional screening and other molecular diagnostic products. Berry Smith has a long history and substantial experience in acting for both private and publicly owned diagnostic businesses. We are very pleased that Yourgene has joined our list of clients operating in this key sector.”
Lyn Rees, C.E.O. of Yourgene said “We are very pleased to welcome our Elucigene colleagues into the Yourgene Health group. The commercial, scientific and financial opportunities created by the acquisition are hugely exciting.
We were very impressed by the commitment, skill and determination demonstrated by the whole team at Berry Smith in achieving the successful completion of the transaction within a challenging timescale.”
If you would like to find out more about Berry Smith Lawyers and think we could assist you and your business then please contact us.
Tel: 029 2034 5511